3 news items
Merck Ends Keytruda Combo Melanoma Study Due to Futility
ANIP
LGND
MRK
14 May 24
monotherapy and combination studies. Merck is also working on different strategies to drive the long-term growth of Keytruda. These include innovative
Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO
LGND
3 Apr 24
. This is consistent with Ligand's strategy to reposition and maximize the value of highly differentiated and promising pharmaceutical assets by combining
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMIâ„¢
LGND
3 Apr 24
to commercialize ZELSUVMI in partnership with a capital provider and/or strategic partner. This is consistent with Ligand's strategy to reposition and maximize
- Prev
- 1
- Next